ClinicalTrials.gg
Not yet recruitingNCT07356037Updated Jan 21, 2026

Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma

A Phase 3 interventional study of Nanocrystalline Megestrol Acetate and Standard Antitumor Therapy in Cachexia and Hepatocellular Carcinoma, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing Megestrol Acetate in Cachexia — 3 open to participants now, 3 under way, 1 of them phase 3. Megestrol Acetate · Cachexia.

Planned enrollment
4th of 12
68 · median 48
Started
2026
with 1 other
Phase 3
7 of 15
1 open now
Registered
14th of 15
by date
Lead sponsor
2 of 15
Changchun GeneScience Pharmaceutical Co., Ltd.

Among the 15 studies testing Megestrol Acetate in Cachexia, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 14th registered.

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

Browse Cachexia studies →

Open to participants now

3 of the 15 studies testing Megestrol Acetate in Cachexia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing Megestrol Acetate in Cachexia, or all of them as a file.
02

Study summary

This study is a prospective, randomized, parallel-controlled clinical trial. The primary objective is to evaluate the superiority and safety of nanocrystalline megestrol acetate in combination with standard therapy compared with standard therapy alone in improving appetite and body mass index (BMI) during treatment in patients with early-stage or locally advanced hepatocellular carcinoma at the cachexia stage.

03

Conditions studied

  • Cachexia
  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with hepatocellular carcinoma who have not previously received systemic therapy and are confirmed by histological or cytological assessment, as evaluated by the investigator, to be unsuitable or ineligible for curative surgical resection; Barcelona Clinic Liver Cancer (BCLC) stage B-C.
  2. class A or B7.
  3. Planned to receive interventional therapy in combination with systemic antitumor therapy.
  4. At least one measurable tumor lesion according to v1.1.
  5. Meet the diagnostic criteria for pre-cachexia or cachexia (based on the Fearon criteria).

Exclusion criteria

Exclusion Criteria:

  1. Presence of any condition affecting gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrolled vomiting; patients receiving tube feeding or parenteral nutrition.
  2. Presence of anorexia due to anorexia nervosa, psychiatric disorders, or pain that makes eating difficult.
  3. Patients with acquired immunodeficiency syndrome (AIDS).
  4. Currently receiving or planning to receive other medications that increase appetite or body weight, such as (except short-term dexamethasone during chemotherapy), androgens, progestins, thalidomide, olanzapine, anamorelin, or other appetite stimulants.
  5. Patients with Cushing's syndrome, adrenal or pituitary insufficiency, or poorly controlled diabetes mellitus.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Nanocrystalline Megestrol Acetate Oral Suspension + Standard Antitumor Therapy

    Nanocrystalline Megestrol Acetate Oral Suspension + Standard Antitumor Therapy

    Drug: Nanocrystalline Megestrol Acetate · Combination Product: Standard Antitumor Therapy

  • Active comparator
    Standard Antitumor Therapy

    Standard Antitumor Therapy

    Combination Product: Standard Antitumor Therapy

Interventions

  • Nanocrystalline Megestrol Acetate oral suspension, with a specification of 125 mg/mL, administered orally at a dose of 5 mL per day (625 mg/day), and the primary endpoint efficacy collection will be conducted in the 4th week.

  • Combination productStandard Antitumor Therapy

    Standard Antitumor Therapy

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with improved appetite based on A/CS-12 assessment.

    Time frame: The proportion of subjects with improved appetite based on A/CS-12 assessment in 12 weeks

Secondary outcomes

  1. Proportion of patients with BMI increase

    Time frame: Proportion of patients with BMI increase in 12 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2026; primary completion for Jun 2027, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2026
First posted
Jan 21, 2026
StartEst.
Jan 10, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07356037
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Jan 10, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 21, 2026

Study contacts

Chang Liu
Contact
drliuchang@wchscu.cn
+86 18180464347

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion